Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Takeda Pharmaceutical Company Limited”

1,022 pharma patents match "Takeda Pharmaceutical Company Limited" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,022
Index total 30,257
Page 13 / 43

Quick answer

This filtered view shows 1,022 pharmaceutical patents matching "Takeda Pharmaceutical Company Limited" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,022 results for “Takeda Pharmaceutical Company Limited” · 30,257 patents in full index Clear search

  1. US 10457670

    Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric modulator activity for the treatment of Alzheimers disease

    Takeda Pharmaceutical Company Limited · Granted Oct 29, 2019 · Expires Oct 24, 2039

    granted
  2. US 10449191

    Treatment of prostate cancer

    Takeda Pharmaceutical Company Limited · Granted Oct 22, 2019 · Expires Oct 17, 2039

    granted
  3. US 10435445

    Peptide compound

    Takeda Pharmaceutical Company Limited · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted
  4. US 10435399

    HDAC6 inhibitory heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted
  5. US 10428056

    Heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Oct 1, 2019 · Expires Sep 26, 2039

    granted
  6. US 10428023

    Heterocyclic compound and use thereof

    Takeda Pharmaceutical Company Limited · Granted Oct 1, 2019 · Expires Sep 26, 2039

    granted
  7. US 10414761

    Cyclopropanamine compound and use thereof

    Takeda Pharmaceutical Company Limited · Granted Sep 17, 2019 · Expires Sep 12, 2039

    granted
  8. US 10407443

    5-HT3 receptor antagonists

    Takeda Pharmaceutical Company Limited · Granted Sep 10, 2019 · Expires Sep 5, 2039

    granted
  9. US 10407409

    6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD

    Takeda Pharmaceutical Company Limited · Granted Sep 10, 2019 · Expires Sep 5, 2039

    granted
  10. US 10406146

    Heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Sep 10, 2019 · Expires Sep 5, 2039

    granted
  11. US 10406157

    Tetrahydropyridopyrazine modulators of GPR6

    Takeda Pharmaceutical Company Limited · Granted Sep 10, 2019 · Expires Sep 5, 2039

    granted
  12. US 10370357

    Method for producing sulfonyl chloride compound

    Takeda Pharmaceutical Company Limited · Granted Aug 6, 2019 · Expires Aug 1, 2039

    granted
  13. US 10357484

    Heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Jul 23, 2019 · Expires Jul 18, 2039

    granted
  14. US 10350170

    Solid preparation

    Takeda Pharmaceutical Company Limited · Granted Jul 16, 2019 · Expires Jul 11, 2039

    granted
  15. US 10351618

    UTI fusion proteins

    Takeda Pharmaceutical Company Limited · Granted Jul 16, 2019 · Expires Jul 11, 2039

    granted
  16. US 10336864

    Production method for poly(amino acid)

    Takeda Pharmaceutical Company Limited · Granted Jul 2, 2019 · Expires Jun 27, 2039

    granted
  17. US 10336833

    Conjugated anti-CD38 antibodies

    Takeda Pharmaceutical Company Limited · Granted Jul 2, 2019 · Expires Jun 27, 2039

    granted
  18. US 10335402

    Sulfonyl piperidine derivatives and their use for treating prokineticin mediated gastrointestinal disorders

    Takeda Pharmaceutical Company Limited · Granted Jul 2, 2019 · Expires Jun 27, 2039

    granted
  19. US 10328089

    Fumagillol derivatives

    Takeda Pharmaceutical Company Limited · Granted Jun 25, 2019 · Expires Jun 20, 2039

    granted
  20. US 10329306

    Crystalline form of 1-(1-methyl-1H-pyrazol-4-yl)-N-((IR,5S,7S)-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-1H-indole-3-carboxamide

    Takeda Pharmaceutical Company Limited · Granted Jun 25, 2019 · Expires Jun 20, 2039

    granted
  21. US 10323027

    2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor

    Takeda Pharmaceutical Company Limited · Granted Jun 18, 2019 · Expires Jun 13, 2039

    granted
  22. US 10323026

    Heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Jun 18, 2019 · Expires Jun 13, 2039

    granted
  23. US 10308605

    Proton pump inhibitors

    Takeda Pharmaceutical Company Limited · Granted Jun 4, 2019 · Expires May 30, 2039

    granted
  24. US 10307414

    Pyridinyl and fused pyridinyl triazolone derivatives

    Takeda Pharmaceutical Company Limited · Granted Jun 4, 2019 · Expires May 30, 2039

    granted